Pembrolizumab (Keytruda®). HTA ID: 25032

Assessment Status Rapid Review Complete
HTA ID 25032
Drug Pembrolizumab
Brand Keytruda®
Indication Pembrolizumab (Keytruda®) in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.
Assessment Process
Rapid review commissioned 24/04/2025
Rapid review completed 21/05/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication compared with the current standard of care.